# Sources — Elvis Presley

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Ivins M. “Elvis Presley Dies; Rock Singer Was 42.” *The New York Times*, August 17, 1977 (On This Day archive). Born in a two-room house in Tupelo on January 8, 1935; the family's move to Memphis when he was 13; his first record in 1953; the Army from 1958; Las Vegas in the 1970s; “used to carry about 175 pounds on a 6-foot frame” but “plagued with overweight”; found at Graceland and pronounced dead at Baptist Memorial Hospital; the medical examiner's preliminary finding of “cardiac arrhythmia,” “a history of mild hypertension” and “evidence of coronary artery disease”; the drugs found being those prescribed “for hypertension and a blockage of the colon, for which he had been hospitalized twice in 1975”; and “It was believed that Mr. Presley neither smoked nor drank.” https://archive.nytimes.com/www.nytimes.com/learning/general/onthisday/big/0816.html
2. “Elvis History: 1974–1977,” Elvis Presley's Graceland (official estate site). The 1974 engagements (Las Vegas January 26 to February 9; tours in March, including Memphis on March 16, 17 and 20; Lake Tahoe May 16 to 26; mid-June; a few weeks off from early July; Las Vegas August 19 to September 2; tour September 27 to October 14, with Lake Tahoe October 11 to 14) and the date of his death. https://www.graceland.com/1974---1977
3. “Elvis Presley was a drug addict and was hospitalized,” United Press International, October 23, 1981. Trial testimony from the hospital records: Baptist Hospital from October 15 to November 1, 1973 (under a false name; “They were withdrawing him from narcotic drugs”), January 28 to February 13, 1975 (abdominal problems; swelling) and August 21 to September 25, 1975 (shortness of breath and swelling); 1,679 addictive pills in 205 days between the 1975 stays; amphetamines mailed from the West Coast; 14 drugs in tissue samples, including codeine at ten times the maximum accepted level; “Absolutely. He was addicted.” https://www.upi.com/Archives/1981/10/23/Elvis-Presley-was-a-drug-addict-and-was-hospitalized/5661372657600/
4. Flippo C. “Elvis Presley: Funeral in Memphis,” *Rolling Stone*, 1977, page 2. An unnamed Baptist Hospital employee: treated for “hypertension, enlarged colon, gastroenteritis, stomach inflammation,” “a severe liver condition,” cortisone treatments, at least 230 pounds; the hospital's doctors discounted a lupus theory. https://www.rollingstone.com/music/music-news/elvis-presley-funeral-in-memphis-61938/2/
5. Zegers RH, Liu KC, Heutink J, Tennant F, Weinreb RN. “Suspicious eyes – Elvis's glaucoma battle.” *J Med Biogr* 2025;33(2):112-115 (PMID 39150457). Abstract only: steroid-induced glaucoma from lifelong prescribed and self-administered steroids; secondary angle closure most likely from anterior uveitis; acute angle-closure glaucoma in 1971; one ophthalmologist from 1971 until his death. https://pubmed.ncbi.nlm.nih.gov/39150457/
6. Murphy P. “Details of Presley's death still unknown,” UPI, November 7, 1981. The acquittal of his physician; 19,000 addictive pills in the last 30 months; the autopsy report never released; the medical examiner's ruling of heart disease; 14 drugs in body tissues; “Drugs may have played a part.” https://www.upi.com/Archives/1981/11/07/Details-of-Presleys-death-still-unknown/2954373957200/
7. “Elvis Presley was a drug addict and received 'staggering' amounts of drugs,” UPI, October 13, 1981. The opening of the trial; prescriptions collected from 140 Memphis-area pharmacies. https://www.upi.com/Archives/1981/10/13/Elvis-Presley-was-a-drug-addict-and-received-staggering/5295371793600/
8. Thorsberg F. “Jurors say Elvis doctor operated in good faith,” UPI, November 5, 1981. The unanimous acquittal and the jurors' reasons (“It was the placebos, the intercepting of drugs”). https://www.upi.com/Archives/1981/11/05/Jurors-say-Elvis-doctor-operated-in-good-faith/6712373784400/
9. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.
10. Wakeman G. “How Did Elvis Presley Die?” HISTORY, February 19, 2026. Found unresponsive on his bathroom floor at Graceland on August 16, 1977; officially attributed to cardiac arrhythmia; The New York Times on the 19,000 doses; and a biographer's account that his physician described a severe megacolon. https://www.history.com/articles/elvis-presley-death-cause

## Clinical guidance

1. Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. *MMWR Recomm Rep* 2022;71(3):1-95 (PMID 36327391): MME, naloxone, monitoring-program checks, urine testing, avoiding opioids with benzodiazepines, and offering medication for opioid use disorder. https://pubmed.ncbi.nlm.nih.gov/36327391/
2. American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. *J Addict Med* 2020;14(2S Suppl 1):1-91 (PMID 32511106). https://pubmed.ncbi.nlm.nih.gov/32511106/
3. Brunner E, et al. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. *J Gen Intern Med* 2025;40(12):2814-2859 (PMID 40526204). https://pubmed.ncbi.nlm.nih.gov/40526204/
4. Centers for Disease Control and Prevention. Prescription Drug Monitoring Programs (PDMPs). https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/prescription-drug-monitoring-programs.html
5. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. *Circulation* 2025;152(11):e114-e218 (PMID 40811497): out-of-office confirmation, a target below 130/80, and starting two first-line drugs, preferably in one pill, for stage 2 hypertension more than 20/10 mmHg above target. https://pubmed.ncbi.nlm.nih.gov/40811497/
6. Grunvald E, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. *Gastroenterology* 2022;163(5):1198-1225 (PMID 36273831). https://pubmed.ncbi.nlm.nih.gov/36273831/
7. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). *N Engl J Med* 2024;391(13):1193-1205 (PMID 38912654). https://pubmed.ncbi.nlm.nih.gov/38912654/
8. Kapur VK, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea. American Academy of Sleep Medicine. *J Clin Sleep Med* 2017;13(3):479-504 (PMID 28162150): in-laboratory polysomnography rather than home testing for patients taking chronic opioids. https://pubmed.ncbi.nlm.nih.gov/28162150/
9. Patil SP, et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure. American Academy of Sleep Medicine. *J Clin Sleep Med* 2019;15(2):335-343 (PMID 30736887). https://pubmed.ncbi.nlm.nih.gov/30736887/
10. Chung F, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology* 2008;108(5):812-821 (PMID 18431116). https://pubmed.ncbi.nlm.nih.gov/18431116/
11. Crockett SD, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. *Gastroenterology* 2019;156(1):218-226 (PMID 30340754). https://pubmed.ncbi.nlm.nih.gov/30340754/
12. Chang L, et al. AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. *Gastroenterology* 2023;164(7):1086-1106 (PMID 37211380). https://pubmed.ncbi.nlm.nih.gov/37211380/
13. Gedde SJ, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern. American Academy of Ophthalmology. *Ophthalmology* 2021;128(1):P71-P150 (PMID 34933745). https://pubmed.ncbi.nlm.nih.gov/34933745/
14. Qaseem A, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med* 2017;166(7):514-530 (PMID 28192789). https://pubmed.ncbi.nlm.nih.gov/28192789/
15. VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide, 2024. https://healthquality.va.gov/HEALTHQUALITY/guidelines/mh/srb/index.asp
16. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), hypertension, glaucoma, and depression, bipolar, and mood disorders monographs. https://patrickrutledge.github.io/topthirty/
17. U.S. Preventive Services Task Force: depression (2023), statins (2022), prediabetes and type 2 diabetes (2021), obesity behavioral interventions (2018), unhealthy drug use (2020), HIV (2019), hepatitis C (2020), unhealthy alcohol use (2018), colorectal cancer (2021), and the A and B recommendations; CDC hepatitis B screening (2023, PMID 36893044) and the Adult Immunization Schedule. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
18. Medicare Preventive Services reference (Aether Forge, 2026). https://patrickrutledge.github.io/preventative_services/

## Editorial resolutions

- **Sources.** The case relies on The New York Times obituary of August 17, 1977 (read in its On This Day archive), Graceland's official timeline, four UPI wire reports of the 1981 trial, the 1977 Rolling Stone report, a 2026 HISTORY article, and the PubMed abstract of Zegers et al. (2025). The Memphis Commercial Appeal could not be reached by the search and fetch tools, and Peter Guralnick's biographies were not read, so neither is cited; the 1977 Rolling Stone report quotes the Commercial Appeal once, but that quotation is not used. The 1980 action of the Tennessee medical board against his physician and the 1979 ABC 20/20 broadcast were found only in secondary sources and are not claims, apart from the UPI mention of the broadcast's conclusion, which is also not used.
- **Recent-death rule.** He died in 1977, so the rule does not apply. Drug and mental-health claims are nonetheless marked sensitive, and the modern episode is synthetic throughout.
- **Index age and dates.** The index visit on July 10, 2026 maps to July 10, 1974, when he was 39: nine months after the October 1973 hospital stay in which, by later testimony, he was withdrawn from narcotic drugs, and during the few weeks off at Graceland that Graceland's timeline places from early July 1974. The synthetic date of birth is January 8, 1987 (shift 52 years). The visits on July 17, August 7 and August 14 map to the weeks off before the Las Vegas engagement of August 19 to September 2, 1974; September 9 and September 23 to the gap between that engagement and the tour of September 27 to October 14; and October 28 to the weeks after the tour. The timeline does not say where he was in each gap; no visit falls on a documented engagement. Past medical history includes only events up to October 1973; the 1975 hospital stays, the prescribing totals, the death and the trial are linked to later timeline events and are left out of the intake documents.
- **Presenting problem.** Fatigue, weight gain, constipation, daytime sleepiness and high blood pressure (R53.83) is the intake problem; it ends at the one-week visit, when the consultation, the polysomnogram and the home readings give the diagnoses of opioid use disorder (F11.20), benzodiazepine use disorder (F13.20), stage 2 hypertension (I10), obstructive sleep apnea (G47.33) and opioid-induced constipation (K59.03), all recorded on that date. Obesity and glaucoma were evident at intake and are recorded then. Intake documents name no diagnosis made later and no later treatment choice.
- **Difference from the panel's existing record of substance use disorders from prescribed drugs.** That record teaches barbiturate and stimulant use disorders from drugs given to a minor, a hospital change to phenobarbital, depression care and CBT for insomnia, with naloxone not indicated. This record teaches a polypharmacy reconciliation across five prescribers, opioid use disorder treated with buprenorphine, two benzodiazepines combined and tapered alongside buprenorphine, naloxone from the first visit, and the cardiometabolic, sleep, bowel and eye consequences of the drugs, with care around touring. The appetite suppressant is stopped as a contraindicated drug, with no stimulant use disorder diagnosed.
- **Drugs in the modern episode.** The documented record names stimulants, sedatives and painkillers in large amounts from several sources. The synthetic drugs are present-day equivalents chosen for teaching (hydromorphone, oxycodone with acetaminophen, diazepam, alprazolam and phentermine); they are not claims about the drugs he took. The roster's “10,000+ doses in the final year” is not used; the case gives the 19,000 doses over about 30 months and the 1,679 pills in 205 days that UPI reported from the trial.
- **Cause of death (CLM-0013, R, disputed).** The medical examiner gave cardiac arrhythmia and later heart disease; trial testimony reported 14 drugs in tissue samples; later accounts emphasize multiple drugs, heart disease, or straining with an enlarged colon. The case records the conflict and assumes none of these. The megacolon account comes second-hand through a biographer quoted in a 2026 article and is R, possible (CLM-0014); the 1977 report of “a blockage of the colon” is D.
- **Liver.** The only source for liver disease is an unnamed hospital employee quoted by Rolling Stone in 1977 (CLM-0005, D, probable). The synthetic episode records mildly raised liver tests that normalize with weight loss and stopping the acetaminophen-containing opioid; no liver diagnosis is coded.
- **Glaucoma (CLM-0007, D; CLM-0008, R, probable).** The 1971 acute angle-closure episode and his ophthalmologist's care are from the Zegers abstract; the steroid explanation is that review's interpretation. The modern diagnosis, glaucoma secondary to drugs (H40.63X1), is synthetic. His ophthalmologist is not named. The modern teaching point is that phentermine, decongestants and anticholinergic sleep aids are avoided in glaucoma, and steroids are used only when essential.
- **Real people.** His physician, George Nichopoulos (who died in 2016), appears only in documented trial history; no modern decision, statement or health fact is attributed to him. The medical examiner and the expert witness are not named. No living person is named. His former wife and his daughter (who died in 2023) are not named and nothing is attributed to either; the social history mentions no family member. Friends who carry naloxone, the advance care planning agent and the household are unnamed and synthetic.
- **Firearms.** The safety assessment records synthetic firearms at home, stored locked and unloaded during the medicine changes. This is a means-safety teaching point and is not linked to any historical claim.
- **DSM-5-TR counts.** Tolerance and withdrawal are counted for both disorders because the drugs were not taken as prescribed (more than prescribed, from several prescribers); the opioid use disorder is severe (seven criteria) and the benzodiazepine use disorder moderate (five). ICD-10-CM codes both as dependence, uncomplicated.
- **Clinical judgment calls.** (1) Buprenorphine was not started at intake, by his choice to see the specialist first; the week in between was covered by naloxone, a single prescriber, seven-day supplies at the verified doses and a locked box. (2) A standard in-office start at COWS 12, rather than a low-dose start. (3) Alprazolam was combined into diazepam at 40 mg a day, a cautious equivalent, and held for three weeks before tapering; steps of about 6 to 11% every five to seven weeks, held during the engagement. (4) Buprenorphine was not withheld because of the benzodiazepine. (5) Amlodipine with valsartan as one pill for stage 2 hypertension more than 10 mmHg above the diastolic target; a thiazide was avoided because of his angle-closure history. (6) Tirzepatide rather than semaglutide because it is approved for obstructive sleep apnea with obesity, started only after buprenorphine was stable and the bowels regular. (7) In-laboratory polysomnography because chronic opioids make home testing unreliable. (8) Phentermine and the diphenhydramine sleep aid were stopped at intake. (9) Acute back pain was managed by splitting buprenorphine, with naproxen and no muscle relaxant or full-agonist opioid. (10) MME uses the CDC 2022 conversion factors (hydromorphone 5, oxycodone 1.5).
- **Instruments.** STOP-Bang, the Epworth Sleepiness Scale and COWS have no LOINC code on the terminology server and are recorded as narrative; the polysomnogram and the point-of-care urine drug tests are recorded as a procedure and in narrative. PHQ-9, GAD-7, DAST-10 and AUDIT-C use LOINC survey codes.
- **Code verification.** The public terminology server returned errors for a time during the build; ICD-10-CM codes were checked first against the NLM Clinical Tables service and then confirmed on the terminology server; LOINC, SNOMED CT, CVX and RxNorm codes were checked on the terminology server and RxNav.
- **Synthetic clinical picture.** Everything in the modern episode is synthetic: the five prescribers, the doses, the urine tests, the diagnoses, the sleep study, every laboratory value and score, the vital signs, the medicines, the back strain and the outcomes. Height (183 cm, about six feet) follows the 1977 obituary; the weights are synthetic.
- **Preventive visit.** A periodic adult preventive visit at 39 (CPT 99395 with 99497 in plain text). Lipids with no statin at 39; prediabetes noted from intake; obesity behavioral counseling; drug-use screening already done; one-time HIV, hepatitis C and hepatitis B screening (HIV and hepatitis C nonreactive, no hepatitis B immunity), so two HepB-CpG doses followed at the ten-week and four-month visits; Tdap; influenza and COVID-19 vaccines in the autumn; colorectal screening not yet due; advance care planning records an unnamed agent.
- **Sick visit.** An acute low back strain after karate practice, chosen because it tests the plan: acute pain on buprenorphine is treated by splitting the dose and adding non-opioid treatment, without a full-agonist opioid, a muscle relaxant that would add sedation, or imaging. Karate is a synthetic detail consistent with the Graceland note that he talked about karate on stage in August 1974; the injury is not a historical claim.
- **Focused visits.** The four chronic-care follow-ups (one week with the consultation, three weeks, ten weeks, four months) are documented as focused visits on ASAM 2020, the 2025 joint benzodiazepine guideline, CDC 2022 and the CDC monitoring-program guidance, the 2025 AHA/ACC guideline and CMID hypertension monograph, the AGA obesity guideline and SURMOUNT-OSA, the AASM guidelines, the AGA constipation guidelines, the AAO pattern and CMID glaucoma monograph, and the CMID depression monograph with the VA/DoD suicide-risk guideline. Two deviations are recorded instead of invented results: (1) the urine drug test due at three weeks was not collected because he left for a rehearsal; no harm was evident (monitoring program clean), and it was collected at the start of the ten-week visit and was as expected; (2) the second weekly video visit during the Las Vegas engagement was missed; a nurse called the next day and found him well, and the corrective action, a fixed weekly time with a same-day backup, held through the tour. Synthetic findings introduced: mild nausea after tirzepatide doses and the back strain.
- **Consultation.** The addiction medicine referral and the consultation by Rosalind Eberhardt-Mensah, MD (a fictional consultant), on the day of the one-week visit, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: severe opioid use disorder and moderate benzodiazepine use disorder, an in-office standard buprenorphine start at 16 mg, alprazolam combined into diazepam 40 mg with a slow taper after buprenorphine was stable, naloxone, the monitoring program, urine testing and weekly contact (the missed test is a recorded deviation), touring arrangements, and the acute-pain plan used at the sick visit.
